The efficacy and security of at present authorized and pipeline drugs for moderate-to-severe hidradenitis suppurativa (HS) are in contrast in a scientific literature assessment and community meta-analysis printed on-line July 2 in JAMA Dermatology.
Amit Garg, M.D., from Northwell in New Hyde Park, New York, and colleagues in contrast the efficacy, security, and tolerability of therapies for moderate-to-severe HS in a scientific literature assessment of part 2 and three randomized scientific trials. Twenty-five trials, together with 5,767 sufferers and 39 distinctive therapies, had obtainable hidradenitis suppurativa scientific response (HiSCR)-50 information.
The researchers discovered that sonelokimab (120 mg each 4 weeks and 240 mg each two weeks), lutikizumab (300 mg each two weeks), adalimumab (40 mg as soon as per week), bimekizumab (320 mg each two weeks and 320 mg each 4 weeks), povorcitinib (15 mg as soon as a day), and secukinumab (300 mg each 4 weeks and 300 mg each two weeks) had been related to considerably increased HiSCR-50 response charges in contrast with placebo.
The variations between adalimumab (40 mg as soon as per week) and different focused therapies had been principally not statistically vital. The proportion of sufferers experiencing severe adversarial occasions ranged from 0% to 10%, 0% to eight%, and 0% to six% within the placebo teams, the adalimumab (40 mg as soon as per week) teams, and the opposite lively remedy teams, respectively.
“These data do not provide strong support for the superiority of one treatment over adalimumab, or vice versa,” the authors write.
Extra info:
Amit Garg et al, Efficacy and Security of Medical Interventions for Reasonable to Extreme Hidradenitis Suppurativa, JAMA Dermatology (2025). DOI: 10.1001/jamadermatol.2025.1976
2025 HealthDay. All rights reserved.
Quotation:
Overview compares efficacy, security of therapies for hidradenitis suppurativa (2025, July 7)
retrieved 7 July 2025
from https://medicalxpress.com/information/2025-07-efficacy-safety-treatments-hidradenitis-suppurativa.html
This doc is topic to copyright. Other than any truthful dealing for the aim of personal examine or analysis, no
half could also be reproduced with out the written permission. The content material is offered for info functions solely.
